WCM
GSK icon

Wallace Capital Management’s GSK GSK Stock Holding History

Wallace Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-74,944
Closed -$3.21M – 80
2024
Q1 		$3.21M Sell
74,944
-2,851
-4% -$118K 0.44% 24
2023
Q4 		$2.88M Sell
77,795
-4,125
-5% -$148K 0.43% 27
2023
Q3 		$2.97M Sell
81,920
-5,158
-6% -$183K 0.46% 27
2023
Q2 		$3.1M Sell
87,078
-405
-0.5% -$14.5K 0.48% 27
2023
Q1 		$3.11M Sell
87,483
-1,973
-2% -$69K 0.51% 29
2022
Q4 		$3.14M Sell
89,456
-16,855
-16% -$561K 0.49% 30
2022
Q3 		$3.13M Sell
106,311
-8,425
-7% -$319K 0.52% 29
2022
Q2 		$6.22M Sell
114,736
-504
-0.4% -$27.8K 0.94% 26
2022
Q1 		$6.44M Sell
115,240
-1,214
-1% -$65.9K 0.97% 25
2021
Q4 		$6.42M Sell
116,454
-7,145
-6% -$372K 0.9% 26
2021
Q3 		$5.9M Sell
123,599
-3,051
-2% -$153K 0.8% 27
2021
Q2 		$6.3M Buy
126,650
+308
+0.2% +$14.8K 0.83% 28
2021
Q1 		$5.95M Sell
126,342
-729
-0.6% -$33.1K 0.78% 30
2020
Q4 		$5.84M Sell
127,071
-6,131
-5% -$282K 0.89% 29
2020
Q3 		$6.27M Sell
133,202
-5,424
-4% -$272K 1.1% 23
2020
Q2 		$7.07M Sell
138,626
-1,326
-0.9% -$68K 1.29% 19
2020
Q1 		$6.63M Sell
139,952
-1,008
-0.7% -$53.8K 1.27% 18
2019
Q4 		$8.28M Sell
140,960
-3,175
-2% -$177K 1.14% 25
2019
Q3 		$7.69M Sell
144,135
-3,224
-2% -$166K 1.01% 27
2019
Q2 		$7.37M Buy
147,359
+197
+0.1% +$9.88K 0.97% 28
2019
Q1 		$7.69M Buy
147,162
+940
+0.6% +$47K 1.06% 27
2018
Q4 		$6.98M Sell
146,222
-29,897
-17% -$1.47M 1.01% 28
2018
Q3 		$8.84M Sell
176,119
-1,023
-0.6% -$52K 1.12% 27
2018
Q2 		$8.93M Buy
177,142
+5,013
+3% +$252K 1.19% 27
2018
Q1 		$8.41M Buy
172,129
+25,188
+17% +$1.17M 1.2% 25
2017
Q4 		$6.51M Buy
146,941
+3,835
+3% +$177K 0.99% 27
2017
Q3 		$7.26M Buy
143,106
+11,504
+9% +$584K 1.16% 23
2017
Q2 		$7.09M Buy
131,602
+3,849
+3% +$205K 1.13% 22
2017
Q1 		$6.73M Buy
127,753
+7,941
+7% +$403K 1.15% 22
2016
Q4 		$5.77M Sell
119,812
-5,494
-4% -$271K 1.05% 24
2016
Q3 		$6.76M Buy
125,306
+3,993
+3% +$219K 1.19% 23
2016
Q2 		$6.57M Buy
121,313
+6,765
+6% +$356K 1.09% 22
2016
Q1 		$5.81M Buy
114,548
+3,453
+3% +$172K 1.03% 22
2015
Q4 		$5.6M Buy
111,095
+2,224
+2% +$113K 1.06% 22
2015
Q3 		$5.23M Buy
108,871
+6,496
+6% +$338K 0.96% 26
2015
Q2 		$5.33M Buy
102,375
+2,670
+3% +$150K 0.93% 25
2015
Q1 		$5.75M Buy
99,705
+7,431
+8% +$426K 1.01% 23
2014
Q4 		$4.93M Buy
92,274
+7,443
+9% +$416K 0.94% 23
2014
Q3 		$4.88M Buy
84,831
+9,616
+13% +$590K 1% 27
2014
Q2 		$5.03M Buy
75,215
+5,185
+7% +$351K 1.06% 25
2014
Q1 		$4.68M Buy
70,030
+1,696
+2% +$115K 1.02% 26
2013
Q4 		$4.56M Buy
68,334
+1,884
+3% +$122K 1.05% 25
2013
Q3 		$4.17M Buy
66,450
+714
+1% +$46K 1.14% 26
2013
Q2 		$4.11M Buy
+65,736
New +$4.17M 1.24% 25

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Wallace Capital Management's GSK Position: Q2 2024 in Review

Wallace Capital Management sold out of GSK (GSK) in Q2 2024, closing a stake of 74,944 shares — an estimated $3.21M sold.

Wallace Capital Management first reported a position in GSK in Q2 2013 and held it in 44 quarters. The position peaked at $8.93M in Q2 2018. 885 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

  • Wallace Capital Management reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
  • Wallace Capital Management sold 74,944 GSK shares in Q2 2024, an estimated $3.21M.
  • Wallace Capital Management first reported a position in GSK in Q2 2013 and held it in 44 quarters.
  • Wallace Capital Management's GSK position peaked at $8.93M in Q2 2018.
  • 885 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Wallace Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.